Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

24.50 +0.11 (+0.45%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday ↗

February 14, 2025

Via Benzinga

(BEAM) - Analyzing Beam Therapeutics's Short Interest ↗

January 31, 2025

Via Benzinga

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

January 30, 2025

From Beam Therapeutics

Via GlobeNewswire

Demystifying Beam Therapeutics: Insights From 4 Analyst Reviews ↗

January 29, 2025

Via Benzinga

Breaking Down Beam Therapeutics: 5 Analysts Share Their Views ↗

November 06, 2024

Via Benzinga

Beam Therapeutics's Earnings: A Preview ↗

November 04, 2024

Via Benzinga

Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings) ↗

September 11, 2024

Via Benzinga

A Closer Look at 5 Analyst Recommendations For Beam Therapeutics ↗

August 22, 2024

Via Benzinga

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

January 23, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

January 13, 2025

From Beam Therapeutics

Via GlobeNewswire

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗

December 20, 2024

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

Via Investor's Business Daily

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 17, 2024

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains ↗

December 09, 2024

Beam Therapeutics unveiled BEAM-101 trial data at ASH, showing improved outcomes in sickle cell patients and promising preclinical BEAM-103 results.

Via Benzinga

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

December 08, 2024

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

December 07, 2024

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

December 06, 2024

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

December 04, 2024

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗

November 26, 2024

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Via Benzinga

Topics Artificial Intelligence

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts ↗

November 25, 2024

Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13.

Via Benzinga

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

November 12, 2024

From Beam Therapeutics

Via GlobeNewswire

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday ↗

November 06, 2024

Via Benzinga

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial ↗

November 05, 2024

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and efficacy results, and progresses on Aalpha-1 Antitrypsin Deficiency

Via Benzinga

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

November 05, 2024

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

November 05, 2024

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

October 29, 2024

From Beam Therapeutics

Via GlobeNewswire

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. ↗

September 26, 2024

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Via Investor's Business Daily

Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating ↗

August 14, 2024

William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1...

Via Benzinga

3 Gene Editing Stocks with Potential to Transform Medicine ↗

August 09, 2024

Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks.

Via InvestorPlace

BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024 ↗

August 06, 2024

BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.